Conflicts of Interest: Pfizer’s Secret Collusion with the NIH

In late February 2023, Moderna agreed to pay $400 million to the National Institute of Allergy and Infectious Diseases (NIAID) for the patent it holds on Moderna’s mRNA shot.¹

The patent process is a part of the COVID mRNA shots that the media haven’t really addressed and people in general don’t know anything about — probably because it’s a total racket. Based on internal documents and correspondence, it appears the NIAID funded the creation of SARS-CoV-2. At the same time, it patented and receives royalty payments for the “vaccine” against said virus.

The National Institutes of Health (NIH) is supposed to be the primary government agency responsible for public health research, but by the looks of it, it appears instead to be in the business of creating public health threats in order to profit from them.

And the agency itself isn’t the only one raking in profits. Many patents are held by individuals working at the NIH/NIAID. So, taxpayers fund research that may or may not work out, while Big Pharma, the NIH and individuals at the NIH profit from products that end up on the market. This is a clear conflict of interest that can hurt public health in any number of ways.

For starters, it incentivizes the NIH to support and promote potentially dangerous drugs, as we’ve clearly seen during the COVID pandemic. The NIH also has a significant stake in regulations that impact patents and vaccine mandates, and may use its influence to benefit itself rather than the public.

But that’s not all. The NIH is also gobbling up patents, which further weakens its incentive to protect and promote what’s truly in the public’s best interest due to the financial conflicts of interest that come into play.